Affymax settles J&J patent suit over anemia program; Mylan snags Pfizer delivery tech; skin cancer drug gets priority review;

 @FierceBiotech: Alkermes keeps drug-delivery ties intact in Lilly-Amylin breakup. Article | Follow @FierceBiotech

 @JohnCFierce: Startup Rhythm (Boston) gets Merck development vet Keith M. Gottesdiener as new CEO. Release | Follow @JohnCFierce

 @RyanMFierce: Mylan is buying Pfizer's respiratory drug delivery tech. Release focus is on COPD. | Follow @RyanMFierce

 @MaureenFierce: Chuck Norris (yes, Chuck Norris) is the newest anti-vaccine activist. Celebrities + science = fun! More | Follow @MaureenFierce

> Could kidney damage biomarkers speed drug development? Article

> Long-term survival in advanced head and neck squamous cell carcinoma (HNSCC) is poor, particularly in China, and the biomarker cyclin D1 (CCND1) is linked with resistance to chemotherapy treatment and worse outcomes. A team of Chinese researchers is working on a CCND1-based assay that could be used to predict which patients would benefit the most from neoadjuvant cisplatin-based chemotherapy before surgery and radiation therapy. Article

> Affymax has agreed to pay up to $13 million to settle patent litigation with J&J over its experimental anemia drug peginesatide. Story

> Look out, GlaxoSmithKline ($GSK). Mylan ($MYL) has snapped up some drug delivery technology from Pfizer ($PFE), aiming to knock off GSK's blockbuster respiratory drugs Advair Diskus and Seretide Diskus. The drugs, which are used to treat asthma and chronic obstructive pulmonary disease, are big sellers for the U.K. drugmaker. Story

> Genentech's skin cancer drug vismodegib has landed priority review status at the FDA, helping to burnish its regulatory prospects and confirm Roche's market-leading position in clinical development. Report

> Almac says it plans to offer some 500 new jobs as it ramps up its development plans. Story

> A small Johns Hopkins biotech spinout is well on its way to meeting its goal of raising a million dollars to back its research on new treatments for eye diseases. Story

Pharma News

 @FiercePharma: Shanghai Pharma's ex-CEO gets suspended death sentence in bribery/graft case. If he behaves, he'll get life in prison News | Follow @FiercePharma

> Class-action securities suit goes forward against. Report

> Amgen Judge orders GSK to mediation in Avandia suits. News

> Pharmacies accuse Pfizer, Ranbaxy of secret Lipitor deal. Report

> Mylan snags Pfizer's Advair copy, inhaler technology. Article

> CBO: Pay-to-delay ban could save $4.8B. Report

Medical Device News

> Pivot secures $32M in Series C. Piece

> FDA clears Cordis' Empira catheters. Item

Drug Delivery News

> Sunovion's inhaled steroid for allergies looks good in Ph3 amid FDA review. More

> Alkermes keeps drug-delivery ties intact in Lilly-Amylin breakup. Story

> Bioject axes 38% of staff as needle-free biz faces revenue, FDA hurdles. Article

> Neuroderm reportedly sees promising data for Parkinson's drug patch. Report

And Finally... Scientists at The University of Nottingham are spearheading a project to develop an in vivo biological cell-equivalent of a computer operating system. Report

Suggested Articles

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.